99% of people have a gene variation
that interferes with medication response.1
79%
have 3 or more gene variations that interfere with medication response.1
Guessing who has these variations contributes to someone dying every two minutes from side effects, and costs the U.S. health system more than treating heart disease, diabetes, or cancer.2
KidSafe Test
Get your child's Opioid Risk and Drug Metabolism results from home — no office visit required. Complete a short intake online, then take the at-home test and return your sample. Once testing is complete, a licensed telehealth clinician reviews the results and signs off before they're released.
If you have a kid, use code KIDSAFE299 at checkout to get the KidSafe Test — Opioid Risk + Drug Metabolism combined — for just $299.
- Opioid Risk + Drug Metabolism, combined into one test
- Reviewed and signed off by a licensed telehealth clinician
- Kit ships to your door with everything included
- Just $299 with code KIDSAFE299 at checkout
Personalized Medicine
Test before you prescribe. Realize the benefits the rest of your life.
Collect the Specimen & Medications
A simple swab and form provide the biological and information specimen we need.
Analysis Instead of Guessing
Instead of “trying a medication out for 30 days,” a clinician can make a better-informed decision on what to prescribe.
Risk Mitigation
Reduce the burden of non-optimized medications by analyzing data to better inform what to prescribe and dose — especially when a patient is taking multiple medications.
Precision Lifesaving Intelligence Using Genetics
We analyze 13 genes across 64 different variations. The TrueMark™ PGx SNP + CNV Real-Time PCR Panel is part of a comprehensive, streamlined pharmacogenomics (PGx) workflow — fixed-content panels with guideline-driven single-nucleotide polymorphism (SNP) and copy number variation (CNV) targets.
250+
medicines currently have PGx testing listed on their FDA-approved labeling.
63% / 29%
of adults / children with pharmacy insurance coverage were prescribed medicines significantly affected by their genes.1
Proove Drug Metabolism runs the same class of lab analysis as other pharmacogenomic tests. What makes it different is how Proove combines that lab analysis with patient data for additional clinical insight. Patients can also choose ongoing AI-powered data updates, so Proove's AI engine refreshes results monthly as new data is published, new guidelines are issued, and new medications are approved — see Proove AI for details and pricing.
The Cost of Guessing
Published clinical and economic evidence on adverse drug events, and what changes when pharmacogenomics is part of prescribing.
Adverse Drug Events Are a Leading Cause of Harm
39% of all inpatient adverse events are adverse drug events. Adverse drug events are the fourth leading cause of death in the U.S. — after heart disease, cancer, and stroke.3
PGx Testing Measurably Reduces Reactions
A 7-country, 18-hospital, 9-health-center, 28-pharmacy randomized study found that PGx panel testing reduced adverse drug reactions by 30% within 12 weeks.4
Lower Utilization Across the Care Continuum
Combining PGx testing with clinical decision support and pharmacist review measurably reduced outpatient visits, ED visits, and inpatient days — both in the months following testing and after hospitalization.5,6
Durable Per-Patient Cost Savings
A comprehensive medication management program combining PGx testing with ongoing clinical review produced cumulative savings of more than $7,000 per patient over 32 months.7
Real-World Comprehensive Medication Management
Outcomes from a pharmacogenomics-enriched CMM program integrated within the EHR for ongoing medication management.7
72
average patient age
13
average medications per patient
4,716 / 36,000
patients PGx tested
$7,000+
savings per patient over 32 months
$218.34
savings per patient per month
Frequently Asked Questions
Answers to the most common questions about Proove Drug Metabolism.
Proove Drug Metabolism runs the same class of lab analysis as other pharmacogenomic tests. What's different is how Proove combines that lab analysis with patient data to provide additional clinical insight — and, for patients who choose ongoing AI-powered updates, Proove's AI engine refreshes your results monthly as new data is published, new guidelines are issued, and new medications are approved. Pricing for ongoing updates is on the Proove AI page.
Optimize Medication Management?
Test before you prescribe, not after something goes wrong.
References
- [1] Li B, et al. Frequencies of pharmacogenomic alleles across biogeographic groups in a large-scale biobank. Am J Hum Genet. 2023 Oct 5;110(10):1628-1647.
- [2] Watanabe JH, McInnis T, Hirsch JD. Cost of Prescription Drug-Related Morbidity and Mortality. Ann Pharmacother. 2018;52(9):829-837.
- [3] Bates DW, Levine DM, Salmasian H, Syrowatka A, Shahian DM, Lipsitz S, Zebrowski JP, Myers LC, Logan MS, Roy CG, Iannaccone C, Frits ML, Volk LA, Dulgarian S, Amato MG, Edrees HH, Sato L, Folcarelli P, Einbinder JS, Reynolds ME, Mort E. The Safety of Inpatient Health Care. N Engl J Med. 2023 Jan 12;388(2):142-153. doi: 10.1056/NEJMsa2206117. PMID: 36630622.
- [4] Swen JJ, van der Wouden CH, Manson LE, et al. A 12-gene pharmacogenetic panel to prevent adverse drug reactions: an open-label, multicentre, controlled, cluster-randomised crossover implementation study. Lancet. 2023;401(10374):347-356.
- [5] Brixner D, Biltaji E, Bress A, Unni S, Ye X, Mamiya T, Ashcraft K, Biskupiak J. The effect of pharmacogenetic profiling with a clinical decision support tool on healthcare resource utilization and estimated costs in the elderly exposed to polypharmacy. J Med Econ. 2016;19(3):213-228. doi: 10.3111/13696998.2015.1110160.
- [6] Elliott LS, Henderson JC, Neradilek MB, Moyer NA, Ashcraft KC, Thirumaran RK. Clinical impact of pharmacogenetic profiling with a clinical decision support tool in polypharmacy home health patients: A prospective pilot randomized controlled trial. PLoS One. 2017 Feb 2;12(2):e0170905. doi: 10.1371/journal.pone.0170905. PMID: 28151991.
- [7] Jarvis JP, Peter AP, Keogh M, Baldasare V, Beanland GM, Wilkerson ZT, Kradel S, Shaman JA. Real-World Impact of a Pharmacogenomics-Enriched Comprehensive Medication Management Program. J Pers Med. 2022;12(3):421. doi: 10.3390/jpm12030421. PMID: 35330421.